1
|
Daugherty EC, Zhang Y, Xiao Z, Mascia AE, Sertorio M, Woo J, McCann C, Russell KJ, Sharma RA, Khuntia D, Bradley JD, Simone CB, Breneman JC, Perentesis JP. FLASH radiotherapy for the treatment of symptomatic bone metastases in the thorax (FAST-02): protocol for a prospective study of a novel radiotherapy approach. Radiat Oncol 2024; 19:34. [PMID: 38475815 PMCID: PMC10935811 DOI: 10.1186/s13014-024-02419-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2023] [Accepted: 02/08/2024] [Indexed: 03/14/2024] Open
Abstract
BACKGROUND FLASH therapy is a treatment technique in which radiation is delivered at ultra-high dose rates (≥ 40 Gy/s). The first-in-human FAST-01 clinical trial demonstrated the clinical feasibility of proton FLASH in the treatment of extremity bone metastases. The objectives of this investigation are to assess the toxicities of treatment and pain relief in study participants with painful thoracic bone metastases treated with FLASH radiotherapy, as well as workflow metrics in a clinical setting. METHODS This single-arm clinical trial is being conducted under an FDA investigational device exemption (IDE) approved for 10 patients with 1-3 painful bone metastases in the thorax, excluding bone metastases in the spine. Treatment will be 8 Gy in a single fraction administered at ≥ 40 Gy/s on a FLASH-enabled proton therapy system delivering a single transmission proton beam. Primary study endpoints are efficacy (pain relief) and safety. Patient questionnaires evaluating pain flare at the treatment site will be completed for 10 consecutive days post-RT. Pain response and adverse events (AEs) will be evaluated on the day of treatment and on day 7, day 15, months 1, 2, 3, 6, 9, and 12, and every 6 months thereafter. The outcomes for clinical workflow feasibility are the occurrence of any device issues as well as time on the treatment table. DISCUSSION This prospective clinical trial will provide clinical data for evaluating the efficacy and safety of proton FLASH for palliation of bony metastases in the thorax. Positive findings will support the further exploration of FLASH radiation for other clinical indications including patient populations treated with curative intent. REGISTRATION ClinicalTrials.gov NCT05524064.
Collapse
Affiliation(s)
- E C Daugherty
- Department of Radiation Oncology, University of Cincinnati, Cincinnati, OH, USA
| | - Y Zhang
- Department of Radiation Oncology, University of Cincinnati, Cincinnati, OH, USA
- Cancer and Blood Disease Institute , Cincinnati Children's Hospital , Cincinnati, OH, USA
| | - Z Xiao
- Department of Radiation Oncology, University of Cincinnati, Cincinnati, OH, USA
- Cancer and Blood Disease Institute , Cincinnati Children's Hospital , Cincinnati, OH, USA
| | - A E Mascia
- Department of Radiation Oncology, University of Cincinnati, Cincinnati, OH, USA
- Cancer and Blood Disease Institute , Cincinnati Children's Hospital , Cincinnati, OH, USA
| | - M Sertorio
- Department of Radiation Oncology, University of Cincinnati, Cincinnati, OH, USA
| | - J Woo
- Varian, a Siemens Healthineers Company, Palo Alto, USA
| | - C McCann
- Varian, a Siemens Healthineers Company, Palo Alto, USA
| | - K J Russell
- Varian, a Siemens Healthineers Company, Palo Alto, USA
| | - R A Sharma
- Varian, a Siemens Healthineers Company, Palo Alto, USA
| | - D Khuntia
- Varian, a Siemens Healthineers Company, Palo Alto, USA
| | - J D Bradley
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA
| | - C B Simone
- Department of Radiation Oncology, New York Proton Center , New York, NY, USA
| | - J C Breneman
- Department of Radiation Oncology, University of Cincinnati, Cincinnati, OH, USA
| | - J P Perentesis
- Cancer and Blood Disease Institute , Cincinnati Children's Hospital , Cincinnati, OH, USA.
| |
Collapse
|
2
|
Hogan JS, Baumann JC, Fischer-Valuck BW, Perez CA, Michalski JM, Karraker P, Vapiwala N, Mehta MP, Bradley JD, Baumann BC. Comparing Changes in Medicare Reimbursement for Radiation Oncology and Medical Oncology (2010-2020). Int J Radiat Oncol Biol Phys 2023; 117:S91. [PMID: 37784604 DOI: 10.1016/j.ijrobp.2023.06.420] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) A recent study found that radiation oncology (RO) has seen significant declines in Medicare reimbursement (MCR) from 2010-2019. While it is presumed that other cancer subspecialties have seen decreasing MCR, to our knowledge, there are no studies directly comparing changes in MCR between RO and other oncology subspecialties. In this study, we analyze changes in MCR from 2010-2020 for both RO and medical oncology. We hypothesized that the declines in MCR will be similar between the two fields. MATERIALS/METHODS The publicly available Physician/Supplier Procedure Summary (PSPS) database was used for all years from 2010-2020. All reimbursement for providers with primary provider codes 92 (RO) and 83 and 90 (heme/onc and medical oncology, respectively) were analyzed. For the 150 most highly-reimbursed HCPCS codes for each specialty in 2010, the total allowed charge for each code was corrected for inflation and then divided by the number of submitted claims to calculate average MCR per code for each year. For each code and each specialty, the 2020 billing frequency was multiplied by the calculated average reimbursement per claim in a given year to calculate what the reimbursement would have been in that year using 2020 dollars and utilization rates (projected reimbursement). The projected reimbursement was summed for all HCPCS codes in each year for each specialty to calculate an aggregate MCR for that specialty for that year. This aggregate MCR was then compared with the actual 2020 reimbursement for that basket of codes to calculate the change in MCR over time. RESULTS Both medical and radiation oncology saw decreases in projected vs. actual MCR from 2010-2020 for this basket of services (Table). Adjusting for inflation and utilization, RO MCR declined by $0.7 billion (B) (-29.0%) from 2010 to 2020 and by $0.2B (-10.5%) from 2015 to 2020 while medical oncology MCR declined by $0.8B (-14.7%) from 2010-2020 and by $0.4B (-6.6%) from 2015-2020. The average decrease per year in projected vs. actual reimbursement for RO was 2.9% (2010 to 2015) and 1.05% (2015 to 2020) and for medical oncology was 1.5% (2010-2015) and 0.7% (2015-2020), respectively. CONCLUSION Adjusting for inflation, Medicare reimbursement for a large array of services has declined for both medical oncology and RO from 2010 - 2020. Contrary to our hypothesis, RO reported a 97% greater relative decline in reimbursement compared with medical oncology from 2010 - 2020. Significant decreases in reimbursement to both fields and their potential implications on patient care and access to care should be considered by policymakers while shifting towards an episode-based Alternative Payment Model and when considering further cuts to Medicare reimbursement.
Collapse
Affiliation(s)
- J S Hogan
- Washington University in St. Louis, St. Louis, MO
| | | | - B W Fischer-Valuck
- Department of Radiation Oncology, Springfield Memorial Hospital, Springfield, IL
| | - C A Perez
- Washington University School of Medicine, Department of Radiation Oncology, St. Louis, MO
| | - J M Michalski
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO
| | - P Karraker
- Washington University School of Medicine, Department of Radiation Oncology, St. Louis, MO
| | - N Vapiwala
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA
| | - M P Mehta
- Miami Cancer Institute, Baptist Health South Florida, Miami, FL
| | - J D Bradley
- Winship Cancer Institute, Emory University, Atlanta, GA
| | - B C Baumann
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO
| |
Collapse
|
3
|
Hu C, Miccio JA, Dignam JJ, Paulus R, Liu C, Skinner HD, Tsakiridis T, Bradley JD, Machtay M. Progression-Free Survival as a Surrogate Endpoint of Overall Survival in Patients with Locally Advanced Non-Small Cell Lung Cancer Treated with Chemoradiotherapy: Trial-Level Meta-Analysis and Individual-Level Analysis of NRG/RTOG 0617 and PROCLAIM. Int J Radiat Oncol Biol Phys 2023; 117:S128. [PMID: 37784328 DOI: 10.1016/j.ijrobp.2023.06.473] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Overall Survival (OS) is the gold standard endpoint in randomized clinical trials (RCTs) of Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC). Intermediate endpoints that can be observed at earlier time points and predict OS would improve trial efficiency and expedite the adoption of proven interventions. MATERIALS/METHODS Atrial-level meta-analysis was conducted using a weighted regression analysis to quantify the correlation between PFS and OS hazard ratios (HRs). Large (n≥ 100) contemporary RCTs in LA-NSCLC that used platinum-based chemoradiation were included. An individual-level surrogacy analysis based on Prentice criteria was performed to evaluate if PFS could reliably predict OS using NRG/RTOG 0617 (NCT00533949), a phase III RCT of dose escalated CRT. The individual-level correlation between PFS and OS was validated using PROCLAIM (NCT00686959) control arm. RESULTS Nineteen RCTs comprising a total of 5525 patients (pts) were included in the trial-level meta-analysis. A moderately high correlation was observed between PFS HR and OS HR (R2 = 0.68, 95% CI = 0.42-0.94). Individual-level analysis of NRG/RTOG 0617 showed that, as reported, RT dose was associated with OS (HR = 1.28, 95% CI = 1.04-1.58, p = 0.02) and PFS (HR = 1.21, 95% CI = 0.99-1.46, p = 0.06). Progressive disease (PD) was highly associated with OS, where pts having PD within 6mo or 12mo had a significantly higher mortality risk than those not having PD within 6mo or 12 mo, respectively, in landmark analysis (PD within 6mo: HR = 2.56, 95% CI = 1.82-3.59, p<0.0001; PD within 12mo: HR = 3.18, 95% CI = 2.45-4.12, p<0.0001). Accounting for PD moderately reduced RT dose effect on OS (HR = 1.21, 95% CI = 0.98-1.49), suggesting RT dose effect on OS may be mediated partially through PD. The association between OS and PD occurrence within 6mo or 12mo was similar in PROCLAIM control arm (PD within 6mo: HR = 2.06, 95% CI = 1.48-2.86, p<0.0001; PD within 12mo: HR = 2.02, 95% CI = 1.38-2.95, p<0.0001). CONCLUSION A moderately high trial-level surrogacy between PFS and OS was identified in trial-level meta-analysis. PD occurrence also reliably predicted OS at the individual patient level in both NRG/RTOG 0617 and PROCLAIM. These results support the use of PFS as a valid endpoint in clinical trials of LA-NSCLC.
Collapse
Affiliation(s)
- C Hu
- Johns Hopkins University School of Medicine, Baltimore, MD; NRG Oncology, Philadelphia, PA
| | - J A Miccio
- Penn State Cancer Institute, Hershey, PA
| | - J J Dignam
- NRG Oncology Statistics and Data Management Center, Philadelphia, PA; University of Chicago, Department of Public Health Sciences, Chicago, IL
| | - R Paulus
- NRG Oncology Statistics and Data Management Center, Philadelphia, PA
| | - C Liu
- Department of Biostatistics, Johns Hopkins University, Baltimore, MD
| | - H D Skinner
- Department of Radiation Oncology, UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA
| | - T Tsakiridis
- Juravinski Cancer Centre, McMaster University, Hamilton,ON, Canada
| | - J D Bradley
- Winship Cancer Institute, Emory University, Atlanta, GA
| | - M Machtay
- Penn State University -Penn State Cancer Institute, Hershey, PA
| |
Collapse
|
4
|
Tian S, McCook A, Choi IJ, Simone CB, Vargas CE, Yu NY, Chang JHC, Mihalcik SA, Tsai H, Zeng J, Rosen LR, Rana ZH, Urbanic JJ, Stokes WA, Kesarwala AH, Bradley JD, Higgins KA. Treatment of Thymoma and Thymic Carcinoma with Proton Beam Therapy: Outcomes from the Proton Collaborative Group Prospective Registry. Int J Radiat Oncol Biol Phys 2023; 117:e66. [PMID: 37785956 DOI: 10.1016/j.ijrobp.2023.06.792] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Given the generally long natural history of thymic malignancies, proton beam therapy (PBT) is advocated to minimize the risk of long-term toxicities to mediastinal organs. Adverse events (AE) and long-term clinical outcomes for this population have not been well-characterized. MATERIALS/METHODS The Proton Collaborative Group registry (NCT01255748), a multi-institutional prospective database of academic and community proton centers in the US, was queried for patients with thymomas and thymic carcinomas treated with PBT. Patients with recurrent/metastatic disease, non-thymic histology, received either prior or palliative radiotherapy (dose < 40 Gy RBE) were excluded. Overall survival (OS) and local control (LC) were estimated using Kaplan-Meier methods. RESULTS A total of 97 patients were identified in the PCG registry. After applying relevant exclusion criteria, 70 patients from 12 proton centers treated from 2011-2021 were included for analysis. Median follow-up length was 16 months. Median age was 58.5 years (IQR 46-63), and 60% were female. 81.4% had a diagnosis of thymoma, and 18.6% thymic carcinoma. 59 patients underwent surgical resection. 11 were treated with definitive PBT, of which 5 received concurrent chemotherapy. Median dose was 54 Gy RBE (range 41.4 - 70 Gy RBE), median number of fractions was 30 (range 21 - 38). 73.4% received pencil beam scanning and 23% uniform scanning PBT. Treatment was overall well-tolerated: a single patient developed grade 4 pneumonitis. Grade 3 AEs were seen in 3 patients - dyspnea, anorexia, and heart failure. Highest grade toxicity experienced was grade 2 for 47.1% and grade 1 for 42.9% of patients. 3-year overall survival (OS) was 82.6% for the entire cohort. 3-year OS was 94% for resected/adjuvant cohort and 35.6% in the non-surgical/definitive cohort. 3-year local control (LC) was 91.7% for the entire cohort. By surgery/margin status, 3-year LC was 96.8% in patients with close or negative margins (a single failure in a patient with close margins), whereas 3-year LC was 55.1% for patients with positive margins/unresectable disease. CONCLUSION Thymic malignancies treated with PBT appear to have favorable outcomes, especially in the adjuvant setting, in this cohort representing the largest series of such patients.
Collapse
Affiliation(s)
- S Tian
- Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, GA
| | - A McCook
- Emory Winship Cancer Institute, Atlanta, GA
| | - I J Choi
- Memorial Sloan Kettering Cancer Center, New York, NY
| | | | - C E Vargas
- Department of Radiation Oncology, Mayo Clinic, Phoenix, AZ
| | - N Y Yu
- Department of Radiation Oncology, Mayo Clinic, Phoenix, AZ
| | - J H C Chang
- The Oklahoma Proton Center, Oklahoma City, OK
| | - S A Mihalcik
- Northwestern Medicine Chicago Proton Center, Warrenville, IL
| | - H Tsai
- Procure Proton Therapy Center, Somerset, NJ
| | - J Zeng
- Department of Radiation Oncology, University of Washington - Fred Hutchinson Cancer Center, Seattle, WA
| | - L R Rosen
- Willis-Knighton Proton Therapy Center, Shreveport, LA
| | - Z H Rana
- Department of Radiation Oncology, University of Maryland Medical Center, Baltimore, MD
| | | | - W A Stokes
- Winship Cancer Institute of Emory University, Department of Radiation Oncology, Atlanta, GA
| | - A H Kesarwala
- Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, GA
| | - J D Bradley
- Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, GA
| | - K A Higgins
- Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, GA
| |
Collapse
|
5
|
Lorenz J, Moghanaki D, Keshava H, Harpole DH, Bradley JD, Higgins KA, Rusthoven CG, Stokes WA. Sins of omission: A meta-research study evaluating the omission of operability in published retrospective comparisons of surgery with stereotactic body radiotherapy in patients with early-stage non-small cell lung cancer. Lung Cancer 2023; 175:57-59. [PMID: 36455397 DOI: 10.1016/j.lungcan.2022.11.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2022] [Accepted: 11/16/2022] [Indexed: 11/21/2022]
Abstract
INTRODUCTION Patients receiving stereotactic body radiotherapy (SBRT) for early-stage non-small cell lung cancer (NSCLC) are typically inoperable, in concordance with guidelines that advocate surgical resection as preferred treatment for operable patients. This differential treatment allocation complicates retrospective comparisons of surgery with SBRT by introducing the potential for confounding by operability. METHODS PubMed was queried for manuscripts reporting primary data from retrospective comparisons of overall survival (OS) between patients undergoing surgery versus SBRT for early-stage NSCLC. Each manuscript was categorized for two outcomes: (1) whether treatment allocation was based on a determination of patient operability, and (2) whether a direct OS comparison between operable SBRT patients and surgically treated patients was included. Associations with variables of interest were measured with statistical significance prespecified at p < 0.10. RESULTS From 3,072 manuscripts identified in our query, sixty-one analyses met screening criteria. Twenty-one (34 %) reported operability status influencing treatment allocation. These were more likely to be published in journals with a surgical focus (52 vs 20 %) and impact factor < 5 (81 vs 58 %), and to contain cohorts from institutional datasets (81 vs 55 %), and to have a radiation oncologist as first (43 vs 25 %) or senior (43 vs 28 %) author. Seven (11 %) manuscripts featured a direct OS comparison between SBRT and surgery. CONCLUSION Nearly-two-thirds of peer-reviewed retrospective studies that have compared OS between surgery and SBRT for early-stage NSCLC lack information on patient operability status, and nearly 90% lack a direct comparison between operable SBRT patients and those receiving surgery.
Collapse
Affiliation(s)
- J Lorenz
- Winship Cancer Institute, Department of Radiation Oncology, Emory University, Atlanta, GA, United States; Emory University, Atlanta, GA, United States.
| | - D Moghanaki
- Atlanta Veterans Affairs Health Care System, Atlanta, GA, United States; Emory University, Atlanta, GA, United States
| | - H Keshava
- University of California Irvine, Irvine, CA, United States; Emory University, Atlanta, GA, United States
| | - D H Harpole
- Duke School of Medicine, Durham, NC, United States; Emory University, Atlanta, GA, United States
| | - J D Bradley
- Winship Cancer Institute, Department of Radiation Oncology, Emory University, Atlanta, GA, United States; Emory University, Atlanta, GA, United States
| | - K A Higgins
- Winship Cancer Institute, Department of Radiation Oncology, Emory University, Atlanta, GA, United States; Emory University, Atlanta, GA, United States
| | - C G Rusthoven
- Emory University, Atlanta, GA, United States; Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, CO, United States
| | - W A Stokes
- Winship Cancer Institute, Department of Radiation Oncology, Emory University, Atlanta, GA, United States; Emory University, Atlanta, GA, United States.
| |
Collapse
|
6
|
Bonomi PD, Gandara D, Hirsch FR, Kerr KM, Obasaju C, Paz-Ares L, Bellomo C, Bradley JD, Bunn PA, Culligan M, Jett JR, Kim ES, Langer CJ, Natale RB, Novello S, Pérol M, Ramalingam SS, Reck M, Reynolds CH, Smit EF, Socinski MA, Spigel DR, Vansteenkiste JF, Wakelee H, Thatcher N. Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer. Ann Oncol 2019; 29:1701-1709. [PMID: 29905778 PMCID: PMC6128180 DOI: 10.1093/annonc/mdy196] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
Background Upregulated expression and aberrant activation of the epidermal growth-factor receptor (EGFR) are found in lung cancer, making EGFR a relevant target for non-small-cell lung cancer (NSCLC). Treatment with anti-EGFR monoclonal antibodies (mAbs) is associated with modest improvement in overall survival in patients with squamous cell lung cancer (SqCLC) who have a significant unmet need for effective treatment options. While there is evidence that using EGFR gene copy number, EGFR mutation, and EGFR protein expression as biomarkers can help select patients who respond to treatment, it is important to consider biomarkers for response in patients treated with combination therapies that include EGFR mAbs. Design Randomized trials of EGFR-directed mAbs cetuximab and necitumumab in combination with chemotherapy, immunotherapy, or antiangiogenic therapy in patients with advanced NSCLC, including SqCLC, were searched in the literature. Results of associations of potential biomarkers and outcomes were summarized. Results Data from phase III clinical trials indicate that patients with NSCLC, including SqCLC, whose tumors express high levels of EGFR protein (H-score of ≥200) and/or gene copy numbers of EGFR (e.g. ≥40% cells with ≥4 EGFR copies as detected by fluorescence in situ hybridization; gene amplification in ≥10% of analyzed cells) derive greater therapeutic benefits from EGFR-directed mAbs. Biomarker data are limited for EGFR mAbs used in combination with immunotherapy and are absent when used in combination with antiangiogenic agents. Conclusions Therapy with EGFR-directed mAbs in combination with chemotherapy is associated with greater clinical benefits in patients with NSCLC, including SqCLC, whose tumors express high levels of EGFR protein and/or have increased EGFR gene copy number. These data support validating the role of these as biomarkers to identify those patients who derive the greatest clinical benefit from EGFR mAb therapy. However, data on biomarkers for EGFR-directed mAbs combined with immunotherapy or antiangiogenic agents remain limited.
Collapse
Affiliation(s)
- P D Bonomi
- Department of Internal Medicine, Rush University Medical Center, Chicago, USA.
| | - D Gandara
- Department of Hematology and Oncology, UC Davis Comprehensive Cancer Center, Sacramento, USA
| | - F R Hirsch
- University of Colorado Cancer Center, Aurora, USA
| | - K M Kerr
- Department of Pathology, Aberdeen University Medical School and Aberdeen Royal Infirmary Foresterhill, Aberdeen, UK
| | - C Obasaju
- Eli Lilly and Company, Indianapolis, USA
| | - L Paz-Ares
- Hospital Universitario Doce de Octubre, Universidad Complutense, CiberOnc & CNIO, Madrid, Spain
| | - C Bellomo
- Intermountain Cancer Center, Cedar City Hospital, Cedar City, USA
| | - J D Bradley
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, USA
| | - P A Bunn
- University of Colorado Cancer Center, Aurora, USA
| | - M Culligan
- Division of Thoracic Surgery, University of Maryland School of Medicine, Baltimore, USA
| | - J R Jett
- Emeritus, National Jewish Health, Denver, USA
| | - E S Kim
- Levine Cancer Institute, Atrium Health, Charlotte, USA
| | - C J Langer
- Department of Thoracic Oncology, University of Pennsylvania Abramson Cancer Center, Philadelphia, USA
| | - R B Natale
- Cedars-Sinai Comprehensive Cancer Center, West Hollywood, USA
| | - S Novello
- Department of Oncology, University of Turin, Turin, Italy
| | - M Pérol
- Department of Medical Oncology, Centre Léon Bérard, Lyon, France
| | - S S Ramalingam
- Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, USA
| | - M Reck
- Lung Clinic Grosshansdorf, Airway Research Center North (ARCN), Member of the German Center for Lung Research (DZL), Grosshansdorf, Germany
| | | | - E F Smit
- Department of Pulmonary Diseases, VU University Medical Center, Amsterdam, the Netherlands
| | | | - D R Spigel
- Sarah Cannon Research Institute, Nashville, USA
| | - J F Vansteenkiste
- Respiratory Oncology Unit, Department of Respiratory Medicine, University Hospital KU Leuven, Leuven, Belgium
| | - H Wakelee
- Stanford University School of Medicine, Stanford, USA
| | - N Thatcher
- The Christie NHS Foundation Trust, Manchester, UK
| |
Collapse
|
7
|
Henke LE, Contreras JA, Green OL, Cai B, Kim H, Roach MC, Olsen JR, Fischer-Valuck B, Mullen DF, Kashani R, Thomas MA, Huang J, Zoberi I, Yang D, Rodriguez V, Bradley JD, Robinson CG, Parikh P, Mutic S, Michalski J. Magnetic Resonance Image-Guided Radiotherapy (MRIgRT): A 4.5-Year Clinical Experience. Clin Oncol (R Coll Radiol) 2018; 30:720-727. [PMID: 30197095 PMCID: PMC6177300 DOI: 10.1016/j.clon.2018.08.010] [Citation(s) in RCA: 98] [Impact Index Per Article: 16.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2018] [Revised: 07/19/2018] [Accepted: 08/21/2018] [Indexed: 10/28/2022]
Abstract
AIMS Magnetic resonance image-guided radiotherapy (MRIgRT) has been clinically implemented since 2014. This technology offers improved soft-tissue visualisation, daily imaging, and intra-fraction real-time imaging without added radiation exposure, and the opportunity for adaptive radiotherapy (ART) to adjust for anatomical changes. Here we share the longest single-institution experience with MRIgRT, focusing on trends and changes in use over the past 4.5 years. MATERIALS AND METHODS We analysed clinical information, including patient demographics, treatment dates, disease sites, dose/fractionation, and clinical trial enrolment for all patients treated at our institution using MRIgRT on a commercially available, integrated 0.35 T MRI, tri-cobalt-60 device from 2014 to 2018. For each patient, factors including disease site, clinical rationale for MRIgRT use, use of ART, and proportion of fractions adapted were summated and compared between individual years of use (2014-2018) to identify shifts in institutional practice patterns. RESULTS Six hundred and forty-two patients were treated with 666 unique treatment courses using MRIgRT at our institution between 2014 and 2018. Breast cancer was the most common disease, with use of cine MRI gating being a particularly important indication, followed by abdominal sites, where the need for cine gating and use of ART drove MRIgRT use. One hundred and ninety patients were treated using ART in 1550 fractions, 67.6% (1050) of which were adapted. ART was primarily used in cancers of the abdomen. Over time, breast and gastrointestinal cancers became increasingly dominant for MRIgRT use, hypofractionated treatment courses became more popular, and gastrointestinal cancers became the principal focus of ART. DISCUSSION MRIgRT is widely applicable within the field of radiation oncology and new clinical uses continue to emerge. At our institution to date, applications such as ART for gastrointestinal cancers and accelerated partial breast irradiation (APBI) for breast cancer have become dominant indications, although this is likely to continue to evolve.
Collapse
Affiliation(s)
- L E Henke
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA
| | - J A Contreras
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA
| | - O L Green
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA
| | - B Cai
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA
| | - H Kim
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA
| | - M C Roach
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA
| | - J R Olsen
- Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, CO, USA
| | - B Fischer-Valuck
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA
| | - D F Mullen
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA
| | - R Kashani
- Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA
| | - M A Thomas
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA
| | - J Huang
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA
| | - I Zoberi
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA
| | - D Yang
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA
| | - V Rodriguez
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA
| | - J D Bradley
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA
| | - C G Robinson
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA
| | - P Parikh
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA
| | - S Mutic
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA
| | - J Michalski
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA.
| |
Collapse
|
8
|
Strand V, Fleischmann R, Alten RE, Koncz T, Zwillich SH, Bradley JD, Gruben D, Wilkinson B, Krishaswami S, Wallenstein G. THU0258 Oral Start: Effects of the Oral JAK Inhibitor Tofacitinib Monotherapy Versus Methotrexate on Patient-Reported Outcomes in the Phase 3 Oral Start Trial of Active Rheumatoid Arthritis. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2013-eular.786] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
9
|
Winthrop KL, Neal J, Hrycaj P, Soma K, Wilkinson B, Hodge J, Zwillich SH, Wang T, Rottinghaus S, Kawabata T, Riese R, Mebus C, Bradley JD, Bingham CO. OP0163 Evaluation of Influenza and Pneumococcal Vaccine Responses in Rheumatoid Arthritis Patients Using Tofacitinib. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2013-eular.368] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
10
|
Zuniga AA, Thorstad WL, Oh JH, Apte AP, Bradley JD, Deasy JO. SU-E-T-38: Validating the Use of a New Tumor Irradiation Quality Metric for Lung and Head and Neck Tumors: Total Clonogen Survival. Med Phys 2011. [DOI: 10.1118/1.3611989] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
11
|
Bradley JD, Stoffer R, Agazzi L, Ay F, Wörhoff K, Pollnau M. Integrated Al2O3:Er3+ ring lasers on silicon with wide wavelength selectivity. Opt Lett 2010; 35:73-75. [PMID: 20664677 DOI: 10.1364/ol.35.000073] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
Integrated Al(2)O(3):Er(3+) channel waveguide ring lasers were realized on thermally oxidized silicon substrates. High pump power coupling into and low laser output power coupling from the ring is achieved in a straightforward design. Output powers of up to 9.5 microW and slope efficiencies of up to 0.11% were measured while lasing was observed for a threshold diode-pump power as low as 6.4 mW for ring lasers with cavity lengths varying from 2.0 to 5.5 cm. Wavelength selection in the range 1530-1557 nm was demonstrated by varying the length of the output coupler from the ring.
Collapse
Affiliation(s)
- J D Bradley
- Integrated Optical Microsystems Group, MESA+ Institute for Nanotechnology, University of Twente, P.O. Box 217, 7500 AE Enschede, The Netherlands.
| | | | | | | | | | | |
Collapse
|
12
|
Heinzerling JH, Hughes RS, Govindan R, Bradley JD, Schiller J, Peng G, Treat J, Obasaju C, Tran T, Choy H. A phase I study of pemetrexed plus carboplatin or cisplatin with concurrent chest radiation therapy (CRT) for patients with locally advanced non-small cell lung cancer (LANSCLC). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.7545] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7545 Background: Pemetrexed is a multi-targeted antifolate that inhibits the synthesis of both pyrimidines and purines. Pemetrexed is an effective new chemotherapeutic agent in advanced non-small cell lung cancer. Pemetrexed has also shown preclinical activity as a radiosensitizer in lung cancer. A phase I study was performed to establish the maximum tolerated dose (MTD) and phase 2 dose of carboplatin or cisplatin given with pemetrexed and CRT in LANSCLC. Methods: Patients (pts) with LANSCLC were enrolled. Initial intent was to establish the MTD of both weekly cisplatin and weekly carboplatin in combination with pemetrexed and CRT as an alternating two-arm phase I trial. Subsequently and based on early results from the CALGB 30407 trial (also evaluating the MTD of carboplatin), the protocol was amended to establish the safety of the planned phase II doses of cisplatin and carboplatin combined with pemetrexed 500 mg/m2 and given every 3 weeks with concurrent CRT. Dose limiting toxicity (DLT) was defined as ≥ Grade 3 hematologic or nonhematologic toxicity based on Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. MTD was determined by occurrence of 2 DLTs among 6 pts in each cohort. Results: 22 pts were enrolled on 3 cohorts. All pts received pemetrexed, 9 with carboplatin AUC=2, 9 with cisplatin 30 mg/m2, and 4 with cisplatin 75 mg/m2. One DLT occurred in each of the carboplatin and cisplatin 30 mg/m2 cohorts, prompting enrollment of 3 additional patients. No DLTs were seen in the cisplatin 75 mg/m2 cohort. Conclusions: The MTD of cisplatin in combination with pemetrexed and CRT was not reached. Based on these results and those from CALGB 30407, either carboplatin AUC=5 or cisplatin 75 mg/m2 in combination with pemetrexed 500 mg/m2 given every 3 weeks with CRT appears to be well tolerated, and are currently being studied in a randomized phase II trial in pts with LANSCLC. [Table: see text]
Collapse
Affiliation(s)
- J. H. Heinzerling
- University of Texas Southwest Medical Center, Dallas, TX; Washington University, St. Louis, MO; Lilly USA, LLC, Indianapolis, IN
| | - R. S. Hughes
- University of Texas Southwest Medical Center, Dallas, TX; Washington University, St. Louis, MO; Lilly USA, LLC, Indianapolis, IN
| | - R. Govindan
- University of Texas Southwest Medical Center, Dallas, TX; Washington University, St. Louis, MO; Lilly USA, LLC, Indianapolis, IN
| | - J. D. Bradley
- University of Texas Southwest Medical Center, Dallas, TX; Washington University, St. Louis, MO; Lilly USA, LLC, Indianapolis, IN
| | - J. Schiller
- University of Texas Southwest Medical Center, Dallas, TX; Washington University, St. Louis, MO; Lilly USA, LLC, Indianapolis, IN
| | - G. Peng
- University of Texas Southwest Medical Center, Dallas, TX; Washington University, St. Louis, MO; Lilly USA, LLC, Indianapolis, IN
| | - J. Treat
- University of Texas Southwest Medical Center, Dallas, TX; Washington University, St. Louis, MO; Lilly USA, LLC, Indianapolis, IN
| | - C. Obasaju
- University of Texas Southwest Medical Center, Dallas, TX; Washington University, St. Louis, MO; Lilly USA, LLC, Indianapolis, IN
| | - T. Tran
- University of Texas Southwest Medical Center, Dallas, TX; Washington University, St. Louis, MO; Lilly USA, LLC, Indianapolis, IN
| | - H. Choy
- University of Texas Southwest Medical Center, Dallas, TX; Washington University, St. Louis, MO; Lilly USA, LLC, Indianapolis, IN
| |
Collapse
|
13
|
Komaki R, Paulus R, Ettinger DS, Videtic GM, Bradley JD, Glisson BS, Choy H. A phase II study of accelerated high-dose thoracic radiation therapy (AHTRT) with concurrent chemotherapy for limited small cell lung cancer: RTOG 0239. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.7527] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7527 Background: Inter-group(IG) study 0096 showed that hyperfractionated and accelerated radiotherapy (HFXART) and concurrent etoposide/cisplatin(EP) improved 5-yr survival (26 %) for patients (pts) with limited small cell lung cancer (LSCLC) compared to daily treatment (TRT) with EP (16%), (p=0.04), HFXART/ EP still had high local failure (LF 40 %) and acute severe esophagitis (ASE) rate (27%). Radiation Therapy Oncology Group (RTOG) 0239 was developed to improve local control (LC) and overall survival (OS) without increasing ASE.Methods: Eligibility included limited stage SCLC, age ≥ 18; P.S. 0–1, with adequate hematologic, hepatic, and renal function. RT was given to large field to 28.8 Gy: 1.8 Gy/ fraction (Fx), 5 days (d) / wk for 16 Fx followed by BID with AP/PA fields in AM @ 1.8 Gy /Fx; boost with 2nd treatment in PM @ 1.8 Gy/Fx on d: 23–26; then off-cord boost, 1.8 Gy, BID, x last 5 days for a total dose of 61.2 Gy in 5 wks. EP was started on day 1 of TRT with P, 60 mg/m2 i.v; E, 120 mg/m2 i.v.; E, 240 mg/m2 p.o. d 2 and 3 or E 120 mg/m2 i.v. / d on d 2 or 3. Repeat cycle every 3 wks x 2 cycles with RT, followed by adjuvant EP alone x 2 cycles. CR pts were asked to participate in the prophylactic cranial irradiation (PCI) study RTOG 0212. RTOG 0239 was designed to detect an improvement in the 2-year survival rate from 47% to 60% with less than 30% of ASE.Results: RTOG 0239 accrued 72 pts (71 eligible) from June 20, 2003 to May 23, 2006. The median follow-up time is 19.0 months for all pts, and 30.4 months for pts still alive. The median age was 63, 52% female, 58% Zubrod PS 0. The 2 -year survival rate was 37 % [95% CI: 25.6, 47.7]. 13 pts (18 %) experienced severe esophagitis. 2 treatment related deaths (2.8%) were reported. Response rates 2 months post RX showed CR 41%, PR 39%, SD 10% and PD 6%. Locoregional control rate at two years was 80%. RT compliance was 95 %.Conclusions: RTOG 0239, AHTRT/EP for LSCLC resulted in 37% 2-year OS, 80% 2 year LC and 18% ASE. Compliance with treatment was high and treatment-related death rate was similar to other chemoradiation regimens. Although 2-year OS did not achieve 60%, excellent LC and low ASE were achieved by RTOG 0239 which became one of 3 arms in an ongoing randomized trial of LSCLC RTOG0538/CALGB30610. [Table: see text]
Collapse
Affiliation(s)
- R. Komaki
- UT M. D. Anderson Cancer Center, Houston, TX; ACR, Philadelphia, PA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Cleveland Clinic Foundation, Cleveland, OH; Washington University Physicans, St. Louis, MO; UT Southwestern Medical Center at Dallas, Dallas, TX
| | - R. Paulus
- UT M. D. Anderson Cancer Center, Houston, TX; ACR, Philadelphia, PA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Cleveland Clinic Foundation, Cleveland, OH; Washington University Physicans, St. Louis, MO; UT Southwestern Medical Center at Dallas, Dallas, TX
| | - D. S. Ettinger
- UT M. D. Anderson Cancer Center, Houston, TX; ACR, Philadelphia, PA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Cleveland Clinic Foundation, Cleveland, OH; Washington University Physicans, St. Louis, MO; UT Southwestern Medical Center at Dallas, Dallas, TX
| | - G. M. Videtic
- UT M. D. Anderson Cancer Center, Houston, TX; ACR, Philadelphia, PA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Cleveland Clinic Foundation, Cleveland, OH; Washington University Physicans, St. Louis, MO; UT Southwestern Medical Center at Dallas, Dallas, TX
| | - J. D. Bradley
- UT M. D. Anderson Cancer Center, Houston, TX; ACR, Philadelphia, PA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Cleveland Clinic Foundation, Cleveland, OH; Washington University Physicans, St. Louis, MO; UT Southwestern Medical Center at Dallas, Dallas, TX
| | - B. S. Glisson
- UT M. D. Anderson Cancer Center, Houston, TX; ACR, Philadelphia, PA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Cleveland Clinic Foundation, Cleveland, OH; Washington University Physicans, St. Louis, MO; UT Southwestern Medical Center at Dallas, Dallas, TX
| | - H. Choy
- UT M. D. Anderson Cancer Center, Houston, TX; ACR, Philadelphia, PA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Cleveland Clinic Foundation, Cleveland, OH; Washington University Physicans, St. Louis, MO; UT Southwestern Medical Center at Dallas, Dallas, TX
| |
Collapse
|
14
|
Chaudhari SR, Goddu SM, Rangaraj D, Pechenaya OL, Lu W, Kintzel E, Malinowski K, Parikh PJ, Bradley JD, Low DA. Dosimetric variances anticipated from breathing- induced tumor motion during tomotherapy treatment delivery. Phys Med Biol 2009; 54:2541-55. [PMID: 19349658 DOI: 10.1088/0031-9155/54/8/019] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
|
15
|
Bradley JD, Cleverly DG, Burns AM, Helm NB, Schmid MJ, Marx DB, Cullen DM, Reinhardt RA. Cyclooxygenase-2 inhibitor reduces simvastatin-induced bone morphogenetic protein-2 and bone formation in vivo. J Periodontal Res 2007; 42:267-73. [PMID: 17451547 PMCID: PMC2014720 DOI: 10.1111/j.1600-0765.2006.00943.x] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
BACKGROUND AND OBJECTIVE Simvastatin, a cholesterol-lowering drug, also stimulates oral bone growth when applied topically, without systemic side-effects. However, the mechanisms involved in vivo are not known. We hypothesized that bone morphogenetic protein-2, nitric oxide synthase, and cyclooxygenase-2 are involved, based on prior in vitro evidence. MATERIAL AND METHODS A rat bilateral mandible model, where 0.5 mg of simvastatin in methylcellulose gel was placed on one side and gel alone on the other, was used to quantify nitric oxide, cyclooxygenase-2 and bone morphogenetic protein-2 (via tissue extraction, enzyme activity or immunoassay), and to analyze the bone formation rate (via undecalcified histomorphometry). Cyclooxygenase-2 and nitric oxide synthase inhibitors (NS-398 and L-NAME, respectively) were administered intraperitoneally. RESULTS Simvastatin was found to stimulate local bone morphogenetic protein-2, nitric oxide and the regional bone formation rate (p < 0.05), whereas NS-398 inhibited bone morphogenetic protein-2 and reduced the bone formation rate (p < 0.05). CONCLUSION These data suggest an association between simvastatin-induced bone morphogenetic protein-2 and bone formation in the mandibular microenvironment, and the negative effect of cyclooxygenase-2 inhibitors on bone growth.
Collapse
Affiliation(s)
- J D Bradley
- Department of Surgical Specialties and Oral Biology, University of Nebraska Medical Center College of Dentistry, Lincoln, NE 68583-0740, USA
| | | | | | | | | | | | | | | |
Collapse
|
16
|
El Naqa I, Suneja G, Lindsay PE, Hope AJ, Alaly JR, Vicic M, Bradley JD, Apte A, Deasy JO. Dose response explorer: an integrated open-source tool for exploring and modelling radiotherapy dose–volume outcome relationships. Phys Med Biol 2006; 51:5719-35. [PMID: 17068361 DOI: 10.1088/0031-9155/51/22/001] [Citation(s) in RCA: 86] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Radiotherapy treatment outcome models are a complicated function of treatment, clinical and biological factors. Our objective is to provide clinicians and scientists with an accurate, flexible and user-friendly software tool to explore radiotherapy outcomes data and build statistical tumour control or normal tissue complications models. The software tool, called the dose response explorer system (DREES), is based on Matlab, and uses a named-field structure array data type. DREES/Matlab in combination with another open-source tool (CERR) provides an environment for analysing treatment outcomes. DREES provides many radiotherapy outcome modelling features, including (1) fitting of analytical normal tissue complication probability (NTCP) and tumour control probability (TCP) models, (2) combined modelling of multiple dose-volume variables (e.g., mean dose, max dose, etc) and clinical factors (age, gender, stage, etc) using multi-term regression modelling, (3) manual or automated selection of logistic or actuarial model variables using bootstrap statistical resampling, (4) estimation of uncertainty in model parameters, (5) performance assessment of univariate and multivariate analyses using Spearman's rank correlation and chi-square statistics, boxplots, nomograms, Kaplan-Meier survival plots, and receiver operating characteristics curves, and (6) graphical capabilities to visualize NTCP or TCP prediction versus selected variable models using various plots. DREES provides clinical researchers with a tool customized for radiotherapy outcome modelling. DREES is freely distributed. We expect to continue developing DREES based on user feedback.
Collapse
Affiliation(s)
- I El Naqa
- Washington University, Saint Louis, MO, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Okawara GS, Winter K, Donohue JH, Pisters PWT, Crane CH, Greskovich JF, Anne PR, Bradley JD, Willet C, Ajani JA. A phase II trial of preoperative chemotherapy and chemoradiotherapy for potentially resectable adenocarcinoma of the stomach (RTOG 99–04). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.4019] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- G. S. Okawara
- McMaster Univ, Hamilton, ON, Canada; Radiation Therapy Oncology Group Headquarters, Philadelphia, PA; Mayo Clinic, Rochester, MN; M.D. Anderson Cancer Ctr, Houston, TX; Univ Hospitals, Cleveland, OH; Thomas Jefferson Univ Hosp, Philadelphia, PA; Washington Univ Sch of Medicine, St Louis, MO; Duke Univ Medcl Ctr, Durham, NC
| | - K. Winter
- McMaster Univ, Hamilton, ON, Canada; Radiation Therapy Oncology Group Headquarters, Philadelphia, PA; Mayo Clinic, Rochester, MN; M.D. Anderson Cancer Ctr, Houston, TX; Univ Hospitals, Cleveland, OH; Thomas Jefferson Univ Hosp, Philadelphia, PA; Washington Univ Sch of Medicine, St Louis, MO; Duke Univ Medcl Ctr, Durham, NC
| | - J. H. Donohue
- McMaster Univ, Hamilton, ON, Canada; Radiation Therapy Oncology Group Headquarters, Philadelphia, PA; Mayo Clinic, Rochester, MN; M.D. Anderson Cancer Ctr, Houston, TX; Univ Hospitals, Cleveland, OH; Thomas Jefferson Univ Hosp, Philadelphia, PA; Washington Univ Sch of Medicine, St Louis, MO; Duke Univ Medcl Ctr, Durham, NC
| | - P. W. T. Pisters
- McMaster Univ, Hamilton, ON, Canada; Radiation Therapy Oncology Group Headquarters, Philadelphia, PA; Mayo Clinic, Rochester, MN; M.D. Anderson Cancer Ctr, Houston, TX; Univ Hospitals, Cleveland, OH; Thomas Jefferson Univ Hosp, Philadelphia, PA; Washington Univ Sch of Medicine, St Louis, MO; Duke Univ Medcl Ctr, Durham, NC
| | - C. H. Crane
- McMaster Univ, Hamilton, ON, Canada; Radiation Therapy Oncology Group Headquarters, Philadelphia, PA; Mayo Clinic, Rochester, MN; M.D. Anderson Cancer Ctr, Houston, TX; Univ Hospitals, Cleveland, OH; Thomas Jefferson Univ Hosp, Philadelphia, PA; Washington Univ Sch of Medicine, St Louis, MO; Duke Univ Medcl Ctr, Durham, NC
| | - J. F. Greskovich
- McMaster Univ, Hamilton, ON, Canada; Radiation Therapy Oncology Group Headquarters, Philadelphia, PA; Mayo Clinic, Rochester, MN; M.D. Anderson Cancer Ctr, Houston, TX; Univ Hospitals, Cleveland, OH; Thomas Jefferson Univ Hosp, Philadelphia, PA; Washington Univ Sch of Medicine, St Louis, MO; Duke Univ Medcl Ctr, Durham, NC
| | - P. R. Anne
- McMaster Univ, Hamilton, ON, Canada; Radiation Therapy Oncology Group Headquarters, Philadelphia, PA; Mayo Clinic, Rochester, MN; M.D. Anderson Cancer Ctr, Houston, TX; Univ Hospitals, Cleveland, OH; Thomas Jefferson Univ Hosp, Philadelphia, PA; Washington Univ Sch of Medicine, St Louis, MO; Duke Univ Medcl Ctr, Durham, NC
| | - J. D. Bradley
- McMaster Univ, Hamilton, ON, Canada; Radiation Therapy Oncology Group Headquarters, Philadelphia, PA; Mayo Clinic, Rochester, MN; M.D. Anderson Cancer Ctr, Houston, TX; Univ Hospitals, Cleveland, OH; Thomas Jefferson Univ Hosp, Philadelphia, PA; Washington Univ Sch of Medicine, St Louis, MO; Duke Univ Medcl Ctr, Durham, NC
| | - C. Willet
- McMaster Univ, Hamilton, ON, Canada; Radiation Therapy Oncology Group Headquarters, Philadelphia, PA; Mayo Clinic, Rochester, MN; M.D. Anderson Cancer Ctr, Houston, TX; Univ Hospitals, Cleveland, OH; Thomas Jefferson Univ Hosp, Philadelphia, PA; Washington Univ Sch of Medicine, St Louis, MO; Duke Univ Medcl Ctr, Durham, NC
| | - J. A. Ajani
- McMaster Univ, Hamilton, ON, Canada; Radiation Therapy Oncology Group Headquarters, Philadelphia, PA; Mayo Clinic, Rochester, MN; M.D. Anderson Cancer Ctr, Houston, TX; Univ Hospitals, Cleveland, OH; Thomas Jefferson Univ Hosp, Philadelphia, PA; Washington Univ Sch of Medicine, St Louis, MO; Duke Univ Medcl Ctr, Durham, NC
| |
Collapse
|
18
|
Bradley JD, Graham M, Suzanne S, Byhardt R, Govindan R, Fowler J, Purdy J, Michalski J, Gore E, Choy H. Phase I results of RTOG L-0117; a phase I/II dose intensification study using 3DCRT and concurrent chemotherapy for patients with Inoperable NSCLC. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.7063] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- J. D. Bradley
- Washington Univ Sch of Medicine, St Louis, MO; Phelps County Regional Medcl Ctr, Rolla, MO; Radiation Therapy Oncology Group, Philadelphia, PA; Medcl Coll of Wisconsin, Milwaukee, WI; Univ of Wisconsin, Madison, WI; Univ of CA Davis, Davis, CA; Univ of Texas Southwestern, Dallas, TX
| | - M. Graham
- Washington Univ Sch of Medicine, St Louis, MO; Phelps County Regional Medcl Ctr, Rolla, MO; Radiation Therapy Oncology Group, Philadelphia, PA; Medcl Coll of Wisconsin, Milwaukee, WI; Univ of Wisconsin, Madison, WI; Univ of CA Davis, Davis, CA; Univ of Texas Southwestern, Dallas, TX
| | - S. Suzanne
- Washington Univ Sch of Medicine, St Louis, MO; Phelps County Regional Medcl Ctr, Rolla, MO; Radiation Therapy Oncology Group, Philadelphia, PA; Medcl Coll of Wisconsin, Milwaukee, WI; Univ of Wisconsin, Madison, WI; Univ of CA Davis, Davis, CA; Univ of Texas Southwestern, Dallas, TX
| | - R. Byhardt
- Washington Univ Sch of Medicine, St Louis, MO; Phelps County Regional Medcl Ctr, Rolla, MO; Radiation Therapy Oncology Group, Philadelphia, PA; Medcl Coll of Wisconsin, Milwaukee, WI; Univ of Wisconsin, Madison, WI; Univ of CA Davis, Davis, CA; Univ of Texas Southwestern, Dallas, TX
| | - R. Govindan
- Washington Univ Sch of Medicine, St Louis, MO; Phelps County Regional Medcl Ctr, Rolla, MO; Radiation Therapy Oncology Group, Philadelphia, PA; Medcl Coll of Wisconsin, Milwaukee, WI; Univ of Wisconsin, Madison, WI; Univ of CA Davis, Davis, CA; Univ of Texas Southwestern, Dallas, TX
| | - J. Fowler
- Washington Univ Sch of Medicine, St Louis, MO; Phelps County Regional Medcl Ctr, Rolla, MO; Radiation Therapy Oncology Group, Philadelphia, PA; Medcl Coll of Wisconsin, Milwaukee, WI; Univ of Wisconsin, Madison, WI; Univ of CA Davis, Davis, CA; Univ of Texas Southwestern, Dallas, TX
| | - J. Purdy
- Washington Univ Sch of Medicine, St Louis, MO; Phelps County Regional Medcl Ctr, Rolla, MO; Radiation Therapy Oncology Group, Philadelphia, PA; Medcl Coll of Wisconsin, Milwaukee, WI; Univ of Wisconsin, Madison, WI; Univ of CA Davis, Davis, CA; Univ of Texas Southwestern, Dallas, TX
| | - J. Michalski
- Washington Univ Sch of Medicine, St Louis, MO; Phelps County Regional Medcl Ctr, Rolla, MO; Radiation Therapy Oncology Group, Philadelphia, PA; Medcl Coll of Wisconsin, Milwaukee, WI; Univ of Wisconsin, Madison, WI; Univ of CA Davis, Davis, CA; Univ of Texas Southwestern, Dallas, TX
| | - E. Gore
- Washington Univ Sch of Medicine, St Louis, MO; Phelps County Regional Medcl Ctr, Rolla, MO; Radiation Therapy Oncology Group, Philadelphia, PA; Medcl Coll of Wisconsin, Milwaukee, WI; Univ of Wisconsin, Madison, WI; Univ of CA Davis, Davis, CA; Univ of Texas Southwestern, Dallas, TX
| | - H. Choy
- Washington Univ Sch of Medicine, St Louis, MO; Phelps County Regional Medcl Ctr, Rolla, MO; Radiation Therapy Oncology Group, Philadelphia, PA; Medcl Coll of Wisconsin, Milwaukee, WI; Univ of Wisconsin, Madison, WI; Univ of CA Davis, Davis, CA; Univ of Texas Southwestern, Dallas, TX
| |
Collapse
|
19
|
Abstract
The objective of this study was to evaluate the potential role of B-type natriuretic peptide (BNP) levels in children with congenital heart disease undergoing cardiac catheterization. Measurement of plasma BNP concentration has been shown to be useful in the diagnosis, risk stratification, and management of adult patients with congestive heart failure, but little is known about the role of BNP in children with structural congenital heart disease. We measured plasma BNP levels using the Triage BNP test in patients with congenital heart disease referred for diagnostic or interventional cardiac catheterization. Plasma BNP concentration was measured in 96 children and 11 adults > or = 19 years old (7.9+/-8.3 years) undergoing heart catheterization for underlying congenital heart disease. BNP levels ranged from < 5 to > 1300 pg/ml, with a median BNP concentration of 19.0 pg/ml. Baseline BNP concentrations were > 100.0 pg/ml on 19 occasions in 17 patients. The pressure difference between the left ventricle and ascending aorta was 10-110 mmHg in 21 patients. BNP concentrations for this cohort ranged from < 5.0 to 1060.0 pg/ml and correlated with the degree of left ventricular outflow obstruction (correlation coefficient, 0.661; p = 0.001). This study suggests that with additional research, BNP concentration may prove to be a useful clinical tool in managing children and adults with congenital heart disease.
Collapse
Affiliation(s)
- C G Cowley
- Division of Pediatric Cardiology, Primary Children's Medical Center, University of Utah, Salt Lake City, UT 84113, USA.
| | | | | |
Collapse
|
20
|
Chung SM, Advani SJ, Bradley JD, Kataoka Y, Vashistha K, Yan SY, Markert JM, Gillespie GY, Whitley RJ, Roizman B, Weichselbaum RR. The use of a genetically engineered herpes simplex virus (R7020) with ionizing radiation for experimental hepatoma. Gene Ther 2002; 9:75-80. [PMID: 11850725 DOI: 10.1038/sj.gt.3301620] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2001] [Accepted: 10/16/2001] [Indexed: 11/08/2022]
Abstract
The herpes simplex virus (HSV) recombinant virus R7020 is an attenuated virus designed as a candidate for immunization against both HSV-1 and HSV-2 infections. It was extensively tested in an experimental animal system and in a healthy human adult population without significant untoward effects. We report on the use of R7020 with ionizing radiation as an oncolytic agent for hepatomas. Two hepatoma cell lines were studied, Hep3B and Huh7. R7020 replicated to higher titers in Hep3B cells than in Huh7 cells. Tissue culture studies correlated with hepatoma xenograft responses to R7020. R7020 was more effective in mediating Hep3B tumor xenograft regression compared with Huh7. Ionizing radiation combined with R7020 also showed differential results in antitumor efficacy between the two cell lines in tumor xenografts. Ionizing radiation enhanced the replication of R7020 in Hep3B xenografts. Moreover, the combination of ionizing radiation and virus caused a greater regression of xenograft volume than either R7020 or radiation alone. Ionizing radiation had no effect on the replication of R7020 virus in Huh7 xenografts. These results indicate that a regimen involving infection with an appropriate herpesvirus such as R7020 in combination with ionizing radiation can be highly effective in eradicating certain tumor xenografts.
Collapse
Affiliation(s)
- S-M Chung
- Department of Radiation and Cellular Oncology, Pritzker School of Medicine, The University of Chicago, Chicago, IL, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Abstract
Attention-deficit/hyperactivity disorder (ADHD) is the most commonly diagnosed disorder in children today with estimated prevalence rates falling between 3 and 5% of children (American Psychiatric Association, 1994). From inception, research has focused on studying varying facets of this disorder with initial efforts primarily focusing on treatment outcome. However, prominent efforts have been made in recent research efforts to shed light on the etiology of this disorder. Such research has discovered the contribution of genetic inheritance, as well as environmental factors that lead to the development of this disorder. Furthermore, studies using neurological and neuropsychological assessment measures have implicated the involvement of various Parts of the brain. This article critically reviews this body of research in light of its impact on the current specific neuropsychologically based etiological theories, as well as the most beneficial directions for future research.
Collapse
Affiliation(s)
- J D Bradley
- Center for Psychological Studies, Nova Southeastern University, Ft Lauderdale, FL 33314, USA
| | | |
Collapse
|
22
|
Abstract
It is widely believed that practical work is an essential part of chemistry education. However, in most countries there is no provision for such personal experiences, and even at universities, provision is limited. This problem has been recognized for many years by both UNESCO and IUPACCTC (Committee on Teaching of Chemistry), and a number of initiatives were taken to address it. The microchemistry program started four years ago aims to address the problem through promoting a small-scale, low-cost approach. This is done by means of introductory workshops for chemistry educators in different countries. The concept has been received enthusiastically in nearly 40 countries now, and pilot projects have been initiated in several of these.
Collapse
Affiliation(s)
- J. D. Bradley
- 1RADMASTE Centre, University of the Witwatersrand, Johannesburg, South Africa
| |
Collapse
|
23
|
Bradley JD. Celecoxib and Rofecoxib: A Distinction with a Difference? J Clin Rheumatol 2001; 7:137-8. [PMID: 17039116 DOI: 10.1097/00124743-200106000-00001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
24
|
Buurman ET, Bradley JD, Donnelly CE, Moore JB, Healy JM, Averett DR, Thompson CM, Wobbe CR. Regulation of both gene expression and protein stability provides genetically assisted target evaluation (GATE) for microbial target validation. Pharmacogenomics 2001; 2:95-106. [PMID: 11368749 DOI: 10.1517/14622416.2.2.95] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
The attempt to develop novel antibiotics, active against organisms resistant to current therapies, has led researchers to seek and explore new drug targets. The rapid sequencing and analysis of entire microbial genomes has identified large numbers of genes that may be sufficiently different from their human counterparts to be exploited as targets for antimicrobial treatment. As a first step, the importance of the various putative targets for microbial growth and survival must be assessed. Emerging validation technologies are becoming increasingly sophisticated and, in certain cases, allow prioritisation of the best targets. In this paper, genetically assisted target evaluation (GATE) is introduced as a versatile target validation technology. GATE concomitantly manipulates both synthesis and stability of the targeted protein using copper ions as an effector. This technology allows rapid quantitation of the lethal consequences of inactivation of targeted gene products in Saccharomyces cerevisiae. Additional tools can then be applied to extend these results into pathogenic organisms, such as Candida albicans.
Collapse
Affiliation(s)
- E T Buurman
- Anadys Pharmaceuticals, Inc., 9050 Camino Santa Fe, San Diego, CA 92121, USA
| | | | | | | | | | | | | | | |
Collapse
|
25
|
Bradley JD, Katz BP, Brandt KD. Severity of knee pain does not predict a better response to an antiinflammatory dose of ibuprofen than to analgesic therapy in patients with osteoarthritis. J Rheumatol 2001; 28:1073-6. [PMID: 11361192] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/16/2023]
Abstract
OBJECTIVE To determine whether greater pain intensity at initiation of treatment predicted better response to ibuprofen than to acetaminophen in subjects with knee osteoarthritis (OA). METHODS Data from 182 patients with knee OA who had taken part in a 4 week randomized, double blind, parallel comparison of 4,000 mg/day acetaminophen vs either 1,200 or 2,400 mg/day ibuprofen were reanalyzed using Pearson correlation coefficients for baseline pain severity, treatment assignment, and treatment response. Pain measures were visual analog scales for overall pain, resting pain, and walking pain. Baseline pain severity was divided into low, medium, and high tertiles, and treatment related differences in pain response were sought with pairwise t tests. Two-factor analysis of variance (ANOVA) models were used to seek interactions between baseline pain severity and treatment group, which would indicate differential drug treatment responsiveness. RESULTS Greater baseline pain predicted greater pain relief with all 3 treatments. Patients with a high level of baseline rest pain appeared to respond better to ibuprofen 2,400 mg/day than to the other treatments, but this difference was not evident after correction for multiple statistical tests. ANOVA did not reveal significant differences in response to the 3 treatments or a significant interaction. CONCLUSION Our data suggest that acetaminophen and ibuprofen are comparably effective in treating knee OA pain, even when the pain is severe.
Collapse
Affiliation(s)
- J D Bradley
- Department of Medicine, Indiana University School of Medicine, Indianapolis, USA
| | | | | |
Collapse
|
26
|
Brandt KD, Bradley JD. Should the initial drug be used to treat osteoarthritis pain be a nonsteroidal antiinflammatory drug? J Rheumatol 2001; 28:467-73. [PMID: 11296943] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
|
27
|
Seiffert D, Bradley JD, Rominger CM, Rominger DH, Yang F, Meredith JE, Wang Q, Roach AH, Thompson LA, Spitz SM, Higaki JN, Prakash SR, Combs AP, Copeland RA, Arneric SP, Hartig PR, Robertson DW, Cordell B, Stern AM, Olson RE, Zaczek R. Presenilin-1 and -2 are molecular targets for gamma-secretase inhibitors. J Biol Chem 2000; 275:34086-91. [PMID: 10915801 DOI: 10.1074/jbc.m005430200] [Citation(s) in RCA: 248] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Presenilins are integral membrane protein involved in the production of amyloid beta-protein. Mutations of the presenilin-1 and -2 gene are associated with familial Alzheimer's disease and are thought to alter gamma-secretase cleavage of the beta-amyloid precursor protein, leading to increased production of longer and more amyloidogenic forms of A beta, the 4-kDa beta-peptide. Here, we show that radiolabeled gamma-secretase inhibitors bind to mammalian cell membranes, and a benzophenone analog specifically photocross-links three major membrane polypeptides. A positive correlation is observed among these compounds for inhibition of cellular A beta formation, inhibition of membrane binding and cross-linking. Immunological techniques establish N- and C-terminal fragments of presenilin-1 as specifically cross-linked polypeptides. Furthermore, binding of gamma-secretase inhibitors to embryonic membranes derived from presenilin-1 knockout embryos is reduced in a gene dose-dependent manner. In addition, C-terminal fragments of presenilin-2 are specifically cross-linked. Taken together, these results indicate that potent and selective gamma-secretase inhibitors block A beta formation by binding to presenilin-1 and -2.
Collapse
Affiliation(s)
- D Seiffert
- DuPont Pharmaceuticals Company, Wilmington, Delaware 19880, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
|
29
|
Crum TA, Teichner G, Bradley JD, Golden CJ. Prediction of WAIS-R indices based on performance on the Luria Nebraska Neuropsychological Battery-III. Int J Neurosci 2000; 101:157-63. [PMID: 10765996 DOI: 10.3109/00207450008986498] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
The purpose of this research was to examine the clinical utility of the Luria-Nebraska Neuropsychological Battery-Third Edition (LNNB-III) in estimating intellectual functioning as measured by the WAIS-R. Ninety-one subjects were administered the WAIS-R and the LNNB-III. Multiple regression were calculated to examine the ability of the LNNB-III clinical scales to predict FSIQ, VIQ, and PIQ indices. The LNNB-III General Intelligence Scale (GI) predicted FSIQ within 10 points 79% of the time, and within 15 points 97% of the time. Similarly, GI predicted VIQ and PIQ indices with 67% accuracy within 10 points and with 91% and 87% accuracy, respectively, within 15 points. A combination of LNNB clinical scales fared no better than GI alone when predicting the FSIQ index. However, a combination of LNNB-III scales predicted VIQ with 80% accuracy within 10 points and with 94% accuracy within 15 points. In contrast, a combination of LNNB-III clinical scales predicted the PIQ index 76% of the time within 10 points and 90% of the time within 15 points. GI appears to be a good alternative when an estimate of intellectual functioning is desired given its less than 10 minute administration time. When greater specificity regarding VIQ and PIQ estimates are desired, a combination of specific LNNB-III scales appear preferable.
Collapse
Affiliation(s)
- T A Crum
- Nova Southeastern University Center for Psychological Studies
| | | | | | | |
Collapse
|
30
|
Bradley JD, Teichner G, Crum TA, Golden CJ. Concurrent validity and analysis of learning curves on the memory scales of the Luria-Nebraska Neuropsychological Battery-Third Edition. Int J Neurosci 2000; 103:115-26. [PMID: 10938568 DOI: 10.3109/00207450009003257] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
The purpose of this investigation was to evaluate the concurrent validity of the Luria-Nebraska Neuropsychological Battery-Third Edition (LNNB-III) memory scales with the WSM-R (study 1), as well as to investigate performance differences between brain-injured and nonbrain injured subjects on the LNNB-III memory indices, first trial learning, and learning curves of each scale (study 2). Study 1 had 90 subjects (46 males and 44 females). Study 2 had 228 subjects (109 normals and 119 brain-injured). Significant correlations were found between the LNNB-III memory scales and the WSM-R index scores. Findings also revealed poorer overall performance and initial learning of brain-injured subjects across all LNNB-III memory scales. Brain-injured subjects also demonstrated significantly reduced learning curves across repeated trials on two of the three scales. The clinical implications of these findings are discussed.
Collapse
|
31
|
Abstract
While the Wisconsin Card Sort Test is a popular procedure used to evaluate executive functions, the test may take extended times to administer, especially in impaired clients. This has led to interest in the development of a short form of the test. Axelrod, Paolo, and Abraham (1997) earlier failed in an attempt to develop a short form of the Wisconsin Card Sort Test (WCST). The authors suggested that a regression-based approach might work better than their predictive model. In a sample of 145 consecutive subjects referred for neuropsychological testing, linear and nonlinear regression formulas were generated to predict the full 128 card version of the test from 32, 64, and 96 item versions of the test. Overall, the data obtained strongly suggests that multiple regression equations can reliably predict WCST whole test scores from a 64 or a 96-item version of the test, but not a 32-item version. The results indicate that the 64-item version is a clinically sound substitute for the entire test.
Collapse
Affiliation(s)
- J Vayalakkara
- Nova Southeastern University, Fort Lauderdale, Florida 33064, USA
| | | | | | | | | |
Collapse
|
32
|
Abstract
The recognition of the role of cytokines in osteoarthritis (OA) has suggested new approaches for therapy of the disease, and also increases the importance of clinical assessment of inflammation. Accurate identification of the presence and degree of inflammation might allow the clinician to predict which individuals would respond to therapy with anti-inflammatory drugs. Several laboratory and clinical markers have been evaluated which may also serve as predictors and indicators of response to therapy and overall outcome.
Collapse
Affiliation(s)
- V T Baddour
- Rheumatology Division, Indiana University School of Medicine, Indianapolis, IN, USA
| | | |
Collapse
|
33
|
Abstract
This research presents data pertaining to the development of the recently revised Luria Nebraska Neuropsychological Battery-III. The final version of this test battery consists of 31 clinical scales yielding 35 scores. The battery was given to 109 non brain-injured controls and 119 brain-injured subjects. High internal consistency was demonstrated for each clinical scale. Results further indicated that the test battery was very effective at discriminating between normal and brain-injured subjects, as significant between-group differences on 33 of 35 scores were observed. Significant between-group differences were also observed on 25 of the 35 scores when age and education were covaried out of the analyses; those scales not displaying significant between-group differences generally measured very basic over-learned skills.
Collapse
Affiliation(s)
- G Teichner
- Nova Southeastern University, Ft. Lauderdale, Florida, USA.
| | | | | | | |
Collapse
|
34
|
Bradley JD, Kataoka Y, Advani S, Chung SM, Arani RB, Gillespie GY, Whitley RJ, Markert JM, Roizman B, Weichselbaum RR. Ionizing radiation improves survival in mice bearing intracranial high-grade gliomas injected with genetically modified herpes simplex virus. Clin Cancer Res 1999; 5:1517-22. [PMID: 10389941] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/13/2023]
Abstract
Malignant gliomas remain incurable with current interventions. Encouraging investigational approaches include the use of genetically modified herpes simplex-1 (HSV-1) viruses as direct cytotoxic agents. Combining attenuated HSV-1 with standard therapy, human U-87 malignant glioma xenografts grown in the hind limb or intracranially in athymic nude mice were exposed to ionizing radiation, inoculated with genetically modified HSV R3616, or received both virus and radiation. The combination of virus with fractionated ionizing radiation suggests a synergistic action and results in reduced tumor volumes and longer survivals when compared with treatment with either modality alone.
Collapse
Affiliation(s)
- J D Bradley
- Department of Radiation and Cellular Oncology, University of Chicago, Illinois 60637, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Batra S, Keipert PE, Bradley JD, Faithfull NS, Flaim SF. Use of a PFC-based oxygen carrier to lower the transfusion trigger in a canine model of hemodilution and surgical blood loss. Adv Exp Med Biol 1997; 411:377-81. [PMID: 9269452 DOI: 10.1007/978-1-4615-5865-1_48] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Affiliation(s)
- S Batra
- Alliance Pharmaceutical Corp., San Diego, California 92121, USA
| | | | | | | | | |
Collapse
|
36
|
Keipert PE, Faithfull NS, Roth DJ, Bradley JD, Batra S, Jochelson P, Flaim KE. Supporting tissue oxygenation during acute surgical bleeding using a perfluorochemical-based oxygen carrier. Adv Exp Med Biol 1996; 388:603-9. [PMID: 8798865 DOI: 10.1007/978-1-4613-0333-6_77] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Affiliation(s)
- P E Keipert
- Alliance Pharmaceutical Corporation, San Diego, CA 92121, USA
| | | | | | | | | | | | | |
Collapse
|
37
|
Pantoliano MW, Horlick RA, Springer BA, Van Dyk DE, Tobery T, Wetmore DR, Lear JD, Nahapetian AT, Bradley JD, Sisk WP. Multivalent ligand-receptor binding interactions in the fibroblast growth factor system produce a cooperative growth factor and heparin mechanism for receptor dimerization. Biochemistry 1994; 33:10229-48. [PMID: 7520751 DOI: 10.1021/bi00200a003] [Citation(s) in RCA: 204] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
The binding interactions for the three primary reactants of the fibroblast growth factor (FGF) system, basic FGF (bFGF), an FGF receptor, FGFR1, and the cofactor heparin/heparan sulfate (HS), were explored by isothermal titrating calorimetry, ultracentrifugation, and molecular modeling. The binding reactions were first dissected into three binary reactions: (1) FGFR1 + bFGF<==>FGFR1/bFGF, K1 = 41 (+/- 12) nM; (2) FGFR1 + HS<==>FGFR1/HS, K2 = 104 (+/- 17) microM; and (3) bFGF + HS<==>bFGF/HS, K3 = 470 (+/- 20) nM, where HS = low MW heparin, approximately 3 kDa. The first, binding of bFGF to FGFR1 in the absence of HS, was found to be a simple binary binding reaction that is enthalpy dominated and characterized by a single equilibrium constant, K1. The conditional reactions of bFGF and FGFR1 in the presence of heparin were then examined under conditions that saturate only the bFGF heparin site (1.5 equiv of HS/bFGF) or saturate the HS binding sites of both bFGF and FGFR1 (1.0 mM HS). Both 3-and 5-kDa low MW heparins increased the affinity for FGFR1 binding to bFGF by approximately 10-fold (Kd = 4.9 +/- 2.0 nM), relative to the reaction with no HS. In addition, HS, at a minimum of 1.5 equiv/bFGF, induced a second FGFR1 molecule to bind to another lower affinity secondary site on bFGF (K4 = 1.9 +/- 0.7 microM) in an entropy-dominated reaction to yield a quaternary complex containing two FGFR1, one bFGF, and at least one HS. Molecular weight estimates by analytical ultracentrifugation of such fully bound complexes were consistent with this proposed composition. To understand these binding reactions in terms of structural components of FGFR1, a three-dimensional model of FGFR1 was constructed using segment match modeling. Electrostatic potential calculations confirmed that an elongated cluster, approximately 15 x 35 A, of nine cationic residues focused positive potential (+2kBT) to the solvent-exposed beta-sheet A, B, E, C' surface of the D(II) domain model, strongly implicating this locus as the HS binding region of FGFR1. Structural models for HS binding to FGFR1, and HS binding to bFGF, were built individually and then assembled to juxtapose adjacent binding sites for receptor and HS on bFGF, against matching proposed growth factor and HS binding sites on FGFR1. The calorimetric binding results and the molecular modeling exercises suggest that bFGF and HS participate in a concerted bridge mechanism for the dimerization of FGFR1 in vitro and presumably for mitogenic signal transduction in vivo.(ABSTRACT TRUNCATED AT 400 WORDS)
Collapse
Affiliation(s)
- M W Pantoliano
- Crystallography and Biophysical Chemistry Group, Du Pont Merck Pharmaceutical Company, Wilmington, Delaware 19880
| | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Bradley JD, Flusser D, Katz BP, Schumacher HR, Brandt KD, Chambers MA, Zonay LJ. A randomized, double blind, placebo controlled trial of intravenous loading with S-adenosylmethionine (SAM) followed by oral SAM therapy in patients with knee osteoarthritis. J Rheumatol Suppl 1994; 21:905-11. [PMID: 8064733] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
OBJECTIVE We evaluated the effectiveness and rapidity of onset of S-adenosylmethionine (SAM), administered as daily intravenous boluses of 400 mg for 5 days, followed by oral tablets, 200 mg thrice daily for 23 days, versus a matching placebo regimen, in the treatment of 81 patients with symptomatic knee osteoarthritis (OA). METHODS The study was bicentric, randomized, double blinded, and placebo controlled. Patients underwent a 7-day washout of arthritis medications prior to initiation of this study treatment. Major outcome measures were the Stanford Health Assessment Questionnaire disability and pain scales, and supplemental visual analog scales for rest and walking pain. RESULTS At one site, patients had milder OA, the baseline characteristics of the treatment groups were well matched, and the SAM treated group showed significantly greater reduction in overall pain and rest pain (p < 0.05) than the placebo treated group. At the other site, the patients had more severe OA, randomization yielded markedly different treatment groups, and the response to treatment did not differ between groups. Onset of SAM effect was seen as early as 14 days after the start of treatment. CONCLUSION SAM may be an effective treatment for some patients with symptomatic knee OA, and merits further study. Intravenous loading before oral maintenance therapy may be advantageous.
Collapse
Affiliation(s)
- J D Bradley
- Specialized Center of Research in Osteoarthritis, Indiana University School of Medicine, Indianapolis 46202
| | | | | | | | | | | | | |
Collapse
|
39
|
Tracy TS, Worster T, Bradley JD, Greene PK, Brater DC. Methotrexate disposition following concomitant administration of ketoprofen, piroxicam and flurbiprofen in patients with rheumatoid arthritis. Br J Clin Pharmacol 1994; 37:453-6. [PMID: 8054251 PMCID: PMC1364901 DOI: 10.1111/j.1365-2125.1994.tb05713.x] [Citation(s) in RCA: 49] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Abstract
The effects of three non-steroidal anti-inflammatory drugs (NSAIDs) on the pharmacokinetics of methotrexate were studied in 10 patients with rheumatoid arthritis. Ketoprofen (3 mg kg-1 day-1), flurbiprofen (3 mg kg-1 day-1), piroxicam (20 mg day-1), or a non-NSAID control (paracetamol/acetaminophen) were administered to patients for at least 6 days (13 days in the case of piroxicam to establish steady state) in a randomized crossover design prior to receiving a weekly oral dose of methotrexate. In the non-NSAID control portion of the study, MTX oral clearance (CLo) was 11.0 +/- 3.9 l h-1, renal clearance (CLR) was 7.9 +/- 2.8 l h-1, percent excreted unchanged was 72 +2- 19% and fraction unbound (fu) was 0.54 +/- 0.11. Values of oral clearance, renal clearance, fraction unbound and percentage excreted unchanged of methotrexate varied no more than 12.2% from non-NSAID control during concomitant administration of ketoprofen, flurbiprofen or piroxicam and were not statistically different from non-NSAID control. In contrast to other NSAIDs such as ibuprofen and salicylates, ketoprofen, flurbiprofen or piroxicam in clinically relevant doses do not appear to affect methotrexate disposition and may be used safely in combination with methotrexate.
Collapse
Affiliation(s)
- T S Tracy
- Department of Basic Pharmaceutical Sciences, School of Pharmacy, West Virginia University, Morgantown 26506
| | | | | | | | | |
Collapse
|
40
|
Abstract
We have developed a new model describing the relationship between plasma and red cell tracers flowing through the lung. The model is the result of an analysis of the transport of radiolabeled plasma albumin between two flowing phases and shows that differences between red cell and plasma tracer curves are related to microvascular hematocrit. The model was tested in an isolated, blood-perfused dog lung preparation in which we injected 51Cr-labeled red cells and 125I-labeled plasma albumin into the pulmonary artery. From the tracer concentration-time curves at the venous outflow, we calculated hr, the ratio of microvascular hematocrit to large-vessel hematocrit. In 18 baseline experiments, hr = 0.92 +/- 0.01 (mn +/- sem) at a blood flow rate of 10.7 +/- 0.3 ml s-1. We determined the effects of (a) glass bead embolization, (b) alloxan, and (c) lobe ligation on hr. Embolization attenuated the separation between plasma and red cells (increased hr), probably as a consequence of passive vasodilation. Alloxan enhanced separation of plasma and red cells (decreased hr), possibly as a result of arteriolar vasoconstriction. Ligation of a fraction of the perfused tissue at constant flow did not cause significant change in hr in the remaining perfused tissue. The model assumes that large-vessel transit times are uniform and that all dispersion occurs in the microvasculature. A theoretical analysis apportioning dispersion between large and small vessels disclosed that the error associated with these assumptions is likely to be less than 15% of the measured hr. We conclude from this study that the microvascular hematocrit model describes experimental plasma and red cell curves. The results imply that hr can be readily deduced from tagged red cells and plasma and can be accounted for in calculating permeability-surface area in diffusing tracer experiments.
Collapse
Affiliation(s)
- K A Overholser
- Department of Biomedical Engineering, Vanderbilt University, Nashville, TN 37235
| | | | | | | | | |
Collapse
|
41
|
Sisk WP, Bradley JD, Leipold RJ, Stoltzfus AM, Ponce de Leon M, Hilf M, Peng C, Cohen GH, Eisenberg RJ. High-level expression and purification of secreted forms of herpes simplex virus type 1 glycoprotein gD synthesized by baculovirus-infected insect cells. J Virol 1994; 68:766-75. [PMID: 8289380 PMCID: PMC236513 DOI: 10.1128/jvi.68.2.766-775.1994] [Citation(s) in RCA: 97] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
Two forms of herpes simplex virus glycoprotein gD were recombined into Autographa californica nuclear polyhedrosis virus (baculovirus) and expressed in infected Spodoptera frugiperda (Sf9) cells. Each protein was truncated at residue 306 of mature gD. One form, gD-1(306t), contains the coding sequence of Patton strain herpes simplex virus type 1 gD; the other, gD-1(QAAt), contains three mutations which eliminate all signals for addition of N-linked oligosaccharides. Prior to recombination, each gene was cloned into the baculovirus transfer vector pVT-Bac, which permits insertion of the gene minus its natural signal peptide in frame with the signal peptide of honeybee melittin. As in the case with many other baculovirus transfer vectors, pVT-Bac also contains the promoter for the baculovirus polyhedrin gene and flanking sequences to permit recombination into the polyhedrin site of baculovirus. Each gD gene was engineered to contain codons for five additional histidine residues following histidine at residue 306, to facilitate purification of the secreted protein on nickel-containing resins. Both forms of gD-1 were abundantly expressed and secreted from infected Sf9 cells, reaching a maximum at 96 h postinfection for gD-1(306t) and 72 h postinfection for gD-1(QAAt). Secretion of the latter protein was less efficient than gD-1(306t), possibly because of the absence of N-linked oligosaccharides from gD-1(QAAt). Purification of the two proteins by a combination of immunoaffinity chromatography, nickel-agarose chromatography, and gel filtration yielded products that were > 99% pure, with excellent recovery. We are able to obtain 20 mg of purified gD-1(306t) and 1 to 5 mg of purified gD-1(QAAt) per liter of infected insect cells grown in suspension. Both proteins reacted with monoclonal antibodies to discontinuous epitopes, indicating that they retain native structure. Use of this system for gD expression makes crystallization trials feasible.
Collapse
Affiliation(s)
- W P Sisk
- DuPont Merck Pharmaceutical Company, Wilmington, Delaware 19880-0400
| | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Keipert PE, Faithfull NS, Bradley JD, Hazard DY, Hogan J, Levisetti MS, Peters RM. Oxygen delivery augmentation by low-dose perfluorochemical emulsion during profound normovolemic hemodilution. Adv Exp Med Biol 1994; 345:197-204. [PMID: 8079708 DOI: 10.1007/978-1-4615-2468-7_26] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Affiliation(s)
- P E Keipert
- Alliance Pharmaceutical Corp., San Diego, CA
| | | | | | | | | | | | | |
Collapse
|
43
|
Leakakos T, Schutt EG, Cavin JC, Smith D, Bradley JD, Strnat CA, del Balzo U, Hazard DY, Otto S, Fields TK. Pulmonary gas trapping differences among animal species in response to intravenous infusion of perfluorocarbon emulsions. Artif Cells Blood Substit Immobil Biotechnol 1994; 22:1199-204. [PMID: 7849923 DOI: 10.3109/10731199409138816] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
In animals, increased lung volume and a concomitant failure of lungs to collapse normally upon autopsy can occur following intravenous injection of higher vapor pressure perfluorocarbons (PFCs) administered as emulsions. Responses vary considerably depending on the PFC, dose and animal model. The study objective was to examine animal species differences with respect to this apparent pulmonary gas trapping (PGT) phenomenon which has not been observed in human clinical trials. A dose-related increase in postmortem lung volume following treatment with either a concentrated perflubron emulsion or Fluosol was observed. It was most pronounced in pigs, rabbits and monkeys, and essentially nonexistent in mice and dogs. No clear effects on arterial blood gases were seen in most species, but PaO2 levels were reduced transiently in monkeys given the highest PFC doses. Reversibility of pulmonary effects occurred more rapidly with perflubron emulsions than with Fluosol. Vacuolated mononuclear cells, reflecting the presence of PFC particles in the lung, and alveolar distention varied between species, but no lesions or edema were observed. Species differences in collateral ventilation, airway morphology and pulmonary intravascular macrophages may influence their sensitivity and contribute to the interspecies differences in response to intravenously administered PFC emulsions.
Collapse
Affiliation(s)
- T Leakakos
- Alliance Pharmaceutical Corp., San Diego, CA 92121
| | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Keipert PE, Faithfull NS, Bradley JD, Hazard DY, Hogan J, Levisetti MS, Peters RM. Enhanced oxygen delivery by perflubron emulsion during acute hemodilution. Artif Cells Blood Substit Immobil Biotechnol 1994; 22:1161-7. [PMID: 7849918 DOI: 10.3109/10731199409138811] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
A high-concentration 90% w/v perflubron (perfluorooctyl bromide [PFOB]) emulsion (Oxygent HT) is being evaluated as an oxygen carrier for use during surgery. This study was done to assess oxygen delivery by Oxygent HT during acute normovolemic hemodilution. Anesthetized mongrel dogs, instrumented with femoral and pulmonary artery catheters, were hemodiluted to a hematocrit of 25% with 3:1 (v/v) of Ringers-lactate (R-L). Dogs were then ventilated with 100% O2 and hemodiluted to a Hct approximately 11% with 1.5 (v/v) of colloid (autologous plasma and 5% albumin). Dogs then received either 3.3 mL/kg Oxygent HT (n = 5) or 3.3 mL/kg R-L (n = 4), and were monitored for 3 hours. Total oxygen delivery (DO2), blood oxygen content, cardiac output, mixed venous PO2, and mixed venous Hb saturation was higher in Oxygent HT treated dogs compared to the R-L controls. The percentage of total DO2 contributed by perflubron-dissolved oxygen was about 8-10% and accounted for 25-30% of total oxygen consumption (VO2). The percentage of VO2 contributed by Hb-carried oxygen was significantly higher in R-L controls (46 +/- 4%) than in the treated dogs (15 +/- 3%), indicating that the availability of the perflubron-dissolved oxygen allowed for a reserve of oxygen to remain available in the red blood cells.
Collapse
Affiliation(s)
- P E Keipert
- Alliance Pharmaceutical Corp., San Diego, CA 92121
| | | | | | | | | | | | | |
Collapse
|
45
|
Brandt KD, Bradley JD. Simple analgesics versus NSAIDs for osteoarthritis. Lancet 1993; 341:770-1. [PMID: 8095684] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
|
46
|
Abstract
Species differences in the longitudinal distribution of pulmonary vascular resistance (PVR) in response to 5-hydroxytryptamine (5-HT) or histamine (His) may be attributed to variations in the distribution of functional smooth muscle between arteries and veins estimated by the response to KCl. Isolated dog, guinea pig, or rabbit lungs were perfused at a constant flow = 55-75 ml.min-1.kg body wt-1. Pulmonary arterial (Ppa); arterial, double, and venous occlusion (Po,a; Pdo; Po,v, respectively); and pulmonary venous (Ppv) pressures were measured before and after increasing PVR by infusing His, 5-HT, or KCl. 5-HT and His increased Ppa--Pdo in rabbits but Pdo--Ppv in guinea pigs. In dogs, 5-HT increased Ppa--Po,a, but His increased Pdo--Ppv. Dynamic (Co,v) and static vascular compliance (CP-Q), as well as critical closing pressure (Pcc, the gamma-intercept of pressure-flow curves), were also measured. At baseline, Co,v was the same among species. However, CP-Q was higher than Co,v in all lungs and was significantly different among species in order of (in ml.cmH2O-1.100 g-1) rabbit (4.54 +/- 0.28) > guinea pig (3.31 +/- 0.18) > dog (2.21 +/- 0.13). Increases in Pcc correlated with increases in microvascular resistance (Po,a--Po,v) but not with increases in PVR after agonist infusion. KCl responses suggest that guinea pigs and rabbits have relatively more functional smooth muscle in venous and arterial microvessels, respectively, whereas dogs have approximately equal amounts.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- J D Bradley
- Department of Anesthesiology, St. Louis University School of Medicine, Missouri 63110
| | | | | |
Collapse
|
47
|
Abstract
The HCl in the mammalian stomach is concentrated enough to digest the stomach itself, yet the gastric epithelium remains undamaged. One protective factor is gastric mucus, which forms a protective layer over the surface epithelium and acts as a diffusion barrier Bicarbonate ions secreted by the gastric epithelium are trapped in the mucus gel, establishing a gradient from pH 1-2 at the lumen to pH 6-7 at the cell surface. How does HCl, secreted at the base of gastric glands by parietal cells, traverse the mucus layer without acidifying it? Here we demonstrate that injection of HCl through solutions of pig gastric mucin produces viscous fingering patterns dependent on pH, mucin concentration and acid flow rate. Above pH 4, discrete fingers are observed, whereas below pH 4, HCl neither penetrates the mucin solution nor forms fingers. Our in vitro results suggest that HCl secreted by the gastric gland can penetrate the mucus gel layer (pH 5-7) through narrow fingers, whereas HCl in the lumen (pH 2) is prevented from diffusing back to the epithelium by the high viscosity of gastric mucus gel on the luminal side.
Collapse
Affiliation(s)
- K R Bhaskar
- Section of Gastroenterology, University Hospital, Boston University Medical Center, Massachusetts 02118
| | | | | | | | | | | | | |
Collapse
|
48
|
Bradley JD, Brandt KD, Katz BP, Kalasinski LA, Ryan SI. Treatment of knee osteoarthritis: relationship of clinical features of joint inflammation to the response to a nonsteroidal antiinflammatory drug or pure analgesic. J Rheumatol 1992; 19:1950-4. [PMID: 1294745] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Our randomized double blinded comparison of acetaminophen versus analgesic and antiinflammatory doses of ibuprofen in the treatment of 182 subjects with knee osteoarthritis (OA) systematically evaluated soft tissue tenderness and joint swelling. Improvement in these signs of joint inflammation was associated with lessening of disability (p = 0.02), and reduction in rest pain (p = 0.07), but not with the drug treatment regimen. Thus, joint tenderness and swelling, presumptive evidence of synovitis, may not be a priori indications for use of an antiinflammatory drug, or predict greater responsiveness to treatment with an antiinflammatory drug than to a pure analgesic, in symptomatic treatment of patients with knee OA.
Collapse
Affiliation(s)
- J D Bradley
- Department of Medicine, Indiana University School of Medicine, Indianapolis 46202-5013
| | | | | | | | | |
Collapse
|
49
|
Abstract
The pharmacokinetics of the enantiomers of ibuprofen have been investigated following oral administration of 300 or 600 mg of racemic ibuprofen four times daily to 45 patients with osteoarthritis. Fifteen of these patients also received single doses of 300 or 600 mg of racemic ibuprofen. Serum concentrations of R- and S-ibuprofen and urine concentrations of the stereoisomers of ibuprofen and its metabolites were measured by high-performance liquid chromatography. The fraction inverted (F(inv)) of the inactive R- to active S-ibuprofen was estimated by a urinary metabolite method. For the 15 patients in both the chronic and single dose studies, there were no significant differences in the clearance of R-ibuprofen or F(inv). The elimination half-lives of R- and S-ibuprofen were comparable for the single and chronic dosing studies. The area under the curve (AUC) values, 6-h trough concentrations, and average steady state concentrations of the R- and S-enantiomers were statistically different after chronic dosing. Despite considerable variability in the clearances in these patients, e.g., clearance (CL) of R-ibuprofen showed 28-49% CV, much less variability was seen in F(inv) (range 9-19% CV), implying that patients would receive similar effective doses of active S-ibuprofen in spite of large differences in kinetics.
Collapse
Affiliation(s)
- A C Rudy
- Department of Medicine, Indiana University School of Medicine, Indianapolis
| | | | | | | | | | | |
Collapse
|
50
|
Zanaboni PB, Bradley JD, Webster RO, Dahms TE. Cyclooxygenase inhibition prevents PMA-induced increase in pulmonary vascular permeability to albumin. J Appl Physiol (1985) 1992; 73:2011-5. [PMID: 1474079 DOI: 10.1152/jappl.1992.73.5.2011] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
In a previous study, we demonstrated that phorbol myristate acetate-(PMA) induced injury in isolated blood-perfused rabbit lungs was characterized by increased pulmonary vascular resistance (PVR) and permeability to water as measured by fluid filtration coefficient (Kf). The Kf increase was prevented by pretreatment with three cyclooxygenase inhibitors, indomethacin, ibuprofen, and meclofenamate. Other studies have shown that PMA causes a decrease in pulmonary vascular surface area, probably due to the increase in arterial resistance. Measurement of Kf requires increased microvascular pressure, and therefore Kf estimates the permeability of the entire vascular bed. Thus the permeability of the flowing vessels may be overestimated by Kf. In this study, we chose to investigate the effect of PMA on vascular permeability to protein by measuring albumin leak. Because this measurement does not require a hydraulic stress, it is more likely to reflect the permeability of flowing vessels. PMA administration (5 x 10(-8) M) caused significant increases in both PVR and 125I-labeled bovine serum albumin leak. Cyclooxygenase inhibition with indomethacin, ibuprofen, or meclofenamate prevented the PMA-induced increase in albumin leak without affecting the PVR increase. These results suggest that cyclooxygenase-mediated products of arachidonic acid mediate the PMA-induced increase in vascular permeability to both water and protein.
Collapse
Affiliation(s)
- P B Zanaboni
- Department of Pharmacology, St. Louis University School of Medicine, Missouri 63104
| | | | | | | |
Collapse
|